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Introduction
Carcinoid tumors occur most commonly in the gas-
trointestinal tract and respiratory tract. Their occur-
rence in other locations is less common. Primary renal
carcinoid tumors are extremely rare lesions of the kid-
ney, with fewer than 60 cases reported previously.1
Due to the small number of reported cases, the behav-
ior of renal carcinoid tumors is not well defined, and
hence it is difficult to predict their prognoses.
Carcinoid tumors are believed to originate from
enterochromafin or amine precursor uptake and decar-
boxylation cells with malignant potential. It has been
hypothesized that renal carcinoid tumors originate from
scattered neuroendocrine cells derived from acquired
or congenital abnormalities, including: (1) metaplasia
of the pyelocaliceal urothelium induced by chronic
inflammation; (2) metastasis from an undiscovered pri-
mary tumor; (3) a misplaced or entrapped neural crest
during embryogenesis; (4) activation of gene sequences
in multipotent primitive stem cells; or (5) concurrent
congenital renal abnormalities.1
Herein, we report a case of primary left renal car-
cinoid tumor with para-aortic lymphadenopathy, syn-
chronous metastases of bilateral liver lobes and bony
metastases based on radiological studies.
Case Report
A 46-year-old man presented with left flank dull ache
initially. On physical examination, there was a palpa-
ble left flank mass and no gross hematuria was noted.
The patient’s general blood routine, urine routine and
renal function examination were within normal ranges.
However, sonography showed a left renal mass with
hypoechoic lesions in the liver. The subsequent abdo-
minal computed tomography (CT) scan showed a left
renal mass, 2 liver masses, para-aortic lymphadenopa-
thy and thoracolumbar spinal lesions (Figure 1A). The
left renal mass was heterogeneous and multilobulated,
with areas of calcification in the periphery (Figure 1B),
and the largest was about 6.5 cm in size. The liver
masses were multiple hypovascular masses over bilateral
lobes. In addition, mixed osteoblastic and osteolytic
lesions over the T12, L1 and L3 vertebral bodies
were noted, hence bony metastasis was considered.
Tumor markers α-fetoprotein, carcinoembryonic anti-
gen, CA153, CA19-9 and squamous cell carcinoma
antigen were within normal limits. There was no leuko-
cytosis and no impaired liver or renal function preop-
eratively. The initial differential diagnoses included
renal cell carcinoma, lymphoma and squamous cell car-
cinoma. However, in consideration of rare renal cancer,
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CT-guided percutaneous biopsy of the left renal mass
was performed, which the pathologist reported to be
only a neoplasm with low malignant potential. We later
performed tumor resection with para-aortic lymph
node dissection, but we did not excise the liver lesions
due to extensive involvement.
The final pathology report indicated a carcinoid
tumor of the left kidney with metastatic para-aortic
lymph node. Advanced immunohistochemistry revealed
that the lesion was positive for neuron-specific enolase
(Figure 2) and CD56, but negative for chromogranin
and synaptophysin. These features are consistent with
a neuroendocrine tumor.
Postoperatively, the patient presented with no spe-
cific carcinoid syndrome after almost 1 year of follow-
up (Figure 3). Chemotherapy regimens seemed to
not show remarkable tumor regression rates,2 so we
did not apply adjuvant chemotherapy postoperatively.
Advanced transarterial embolization for hepatic metas-
tases was arranged 1 year later due to the patient’s
personal reasons.
Discussion
The biochemical features of a typical carcinoid tumor,
usually the midgut type, include the enzyme dopa
decarboxylase, which converts 5-hydroxytryptophan
into serotonin, which in turn develops into clinical
carcinoid syndrome, including flushing, diarrhea, and
bronchospasm.2 However, only a few patients, even
among those with gastrointestinal tract carcinoid
tumor, have been reported to present with these classic
symptoms, making the preoperative diagnosis of this
disease difficult. Primary renal carcinoid tumor seldom
has these biochemical manifestations and is indolent
in nature. Patients who have a renal carcinoid tumor
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Figure 1. (A) Abdominal computed tomography (CT) shows a left renal mass with para-aortic lymphadenopathy. (B) Abdominal CT shows
that the left renal mass is heterogeneous and multilobulated, with areas of calcification in the periphery.
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Figure 2. The tumors are composed of monomorphous cells
arranged in trabecular tubulocystic and sheet-like patterns with
positive staining for neuron-specific enolase.
Figure 3. Abdominal computed tomography shows the follow-up
image about 1 year postoperatively.
usually have a huge tumor burden of about 8.4 cm
when diagnosed.1 Urinary 5-hydroxyindoleacetic acid
level measured in a 24-hour urine sample test is the
most common work-up for carcinoid tumors. How-
ever, it lacks sensitivity and specificity in the diagnosis
of carcinoid syndrome because it may also be elevated
in other conditions such as tropical sprue, celiac dis-
ease, Whipple’s disease and small bowel obstruction.2
To date, no biochemical test has been developed to
determine whether a known, endocrinologically silent
renal mass is a carcinoid tumor. In our case, the pa-
tient did not have classic carcinoid syndrome, and that
made it difficult to find a clinical link with neuroen-
docrine tumor.
In addition, the 3 most common renal carcinoid
metastatic sites are the peri-aortic or perihilar lymph
nodes, liver, and bones in sequence. As Romero and
colleagues reported, good prognostic factors are age
younger than 40 years, tumor size < 4 cm, and mitotic
rate < 1/10 per high-powered field.1 In other previous
reports,3,4 the correlation of renal carcinoid tumor
and horseshoe kidney was discussed. It was concluded
that the relative risk of renal carcinoid tumor develop-
ing into a horseshoe kidney is markedly greater than
that for Wilms’ tumor or transitional cell carcinoma,
yielding a calculated relative risk of 62.3–5
With regard to imaging modalities, renal carcinoid
tumors have a tendency to present with minimal or
poor enhancement on contrast-enhanced CT, corre-
sponding to hypovascular or avascular lesions on renal
angiography. Though octreotide scintigraphy was in-
troduced as a sensitive imaging modality for the diag-
nosis and staging of carcinoid tumors, it may also play
a major role in the detection of residual tumor or
metastases.6
Radiologically, abdominal CT in our patient showed
that the renal carcinoid tumor was multilobulated and
hypovascular, with calcification of the periphery. In
addition, the enlarged para-aortic lymph node and
multiple low-signal-intensity lesions of the liver made
us suspect an unusual renal tumor. Thus, CT-guided
percutaneous biopsy was performed to rule out the
possibility of other types of rare renal tumors. How-
ever, the pathologist only reported the lesion to be a
neoplasm with low malignant potential. In such cases,
it is difficult for the clinician to determine the next step.
Surgically, unlike Gedaly and colleagues, who per-
formed extensive radical resection of the tumor includ-
ing hepatectomy,7 we performed radical nephrectomy
of the renal tumor with lymphadenectomy but left
the liver lesions for further treatment. During the
operation, the pathologist reported that a frozen sec-
tion of the tumor was a carcinoid. However, definitive
diagnosis depended on immunohistochemistry stain
with neuron-specific enolase, chromogranin, synapto-
physin, glucagons, vasoactive intestinal peptide, sero-
tonin, and somatostatin.
Recently, long-acting somatostatin analogs have
been shown to be effective in controlling carcinoid
syndrome. Previously, the use of indium-labeled oct-
reotide or 131I-metaiodobenzylguanidine in receptor-
targeted radionuclide therapy was reported to be
beneficial symptomatically.2 In addition, high-dose
octreotide has also been reported to reduce symp-
toms and biochemical markers as well as tumor load.
The role of chemotherapy, such as streptozotocin-
doxorubicin, streptozotocin plus 5-fluorouracil or
dacarbazine, is limited due to poor response rate and
toxicity. Even though a 50% biochemical response has
been reported with a regimen of interferon combined
with 5-fluorouracil, it is not recommended due to
poor tolerance.2
In conclusion, further study is needed to determine
the best treatment modality for rare renal tumors. Early
radical debulking surgery of the tumor may improve
cancer-free survival, but it could also lead to severe peri-
operative morbidity. Less radical surgery with adjuvant
therapeutic planning may be a better choice.
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